EMERYVILLE, Calif., April 1, 2008 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII), today announced that, effective April 1, 2008, Matthew M. Loar has been appointed Chief Financial Officer. Mr. Loar will be based at the Company's headquarters in Emeryville. Mr. Loar joins the company from Osteologix, where he has served as Chief Financial Officer since 2006.
"Matt has a proven track record as a chief financial officer, and we will look to his expertise to help guide our financial and business strategy," said Paul E. Freiman, President and Chief Executive Officer of Neurobiological Technologies. "His wealth of experience in helping to run several businesses combined with his knowledge of industry accounting requirements, SEC compliance and the biotech investment community will be real assets as our team continues to advance our strategic vision."
Mr. Loar is a Certified Public Accountant and has over twenty years experience in finance and accounting. Mr. Loar has a strong track record working with growing pharmaceutical and biotechnology companies, and has played a key role in several major corporate collaborations, successfully completing public and private equity financings and implementing the provisions of Sarbanes-Oxley Act at a public biotechnology company.
"NTI has a strong management team, a unique product development strategy, and tremendous potential for their phase 3 investigational drug, Viprinex(TM).
I look forward to becoming a key contributor to their future growth,"
said Mr. Loar. "NTI's efforts to develop new and improved central nervous
system therapeutics are indeed exciting, and I'm anxious to start working
with the other members of NTI's team to maximize
|SOURCE Neurobiological Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved